Invoice Requirement. Unless otherwise specified herein, any amounts payable to Infinity hereunder shall be made in U.S. dollars within forty-five (45) calendar days after receipt by Novartis, or its nominee designated for that purpose in advance by Novartis in writing to Infinity, of an invoice (in the form attached as Exhibit D) covering such payment.
Invoice Requirement. Any amounts payable to VERTEX hereunder (except any royalty payments required to be made under the provisions of Section 6.3 hereof) shall be made within thirty days after receipt by NOVARTIS, or its nominee designated for that purpose in advance by NOVARTIS in writing to VERTEX, of an invoice covering such payment, which invoice shall conform to the extent reasonably practicable to the form of invoice contained in Exhibit B to the Research Agreement.
Invoice Requirement. Any amounts payable to Vertex hereunder shall be made within thirty days after receipt by CFFT, or its nominee designated for that purpose in advance by CFFT in writing to Vertex, of an invoice covering such payment.
Invoice Requirement. Invoicing for Call Orders shall be submitted in accordance with the BPA terms and conditions, Call Order clauses and requirements. Invoicing may commence upon acceptance of each or all deliverables by an authorized official Invoicing shall include all supporting documents for the invoiced amount.
Invoice Requirement. 58 15.18 Hardship........................................................58 SCHEDULES Schedule 1.12 -- List of Drug Product Candidates Schedule 1.25 -- List of Major Markets Schedule 1.29 -- NOVARTIS Patents Schedule 1.44 -- VERTEX Patents Schedule 4.6 -- Terms of Supply License, Development and Commercialization Agreement -- Confidential -- Table of Contents -- Page iii License, Development and Commercialization Agreement This Agreement is made and entered into as of ________, _____ (the "Effective Date") between Vertex Pharmaceuticals Incorporated (hereinafter "VERTEX"), a Massachusetts corporation with principal offices at 000 Xxxxxxx Xxxxxx, Xxxxxxxxx, XX 00000-0000, and NOVARTIS PHARMA AG (hereinafter "NOVARTIS"), a Swiss corporation with principal offices at XX-0000 Xxxxx, Xxxxxxxxxxx.
Invoice Requirement. Any amounts payable to Myogen hereunder (except any royalty payments required to be made under the provisions of Article IV of the License Agreement) shall be made within thirty (30) days after receipt by NIBRI, or its nominee designated for that purpose in advance by NIBRI in writing to Myogen, of an invoice covering such payment. [Signature page follows] [/\#/\]CONFIDENTIAL TREATMENT REQUESTED Collaboration and Option Agreement - Confidential - Page 41 MYOGEN, INC. By: /s/ J. William Freytag ---------------------------------------------- J. William Freytag Title: President axx Xxxxx Xxxxxxive Officer NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. By: /s/ Mark Fishman ---------------------------------------------- Mark Fishman, M.D. Title: Presidenx xxx Xxxxx Executive Officer [/\#/\]CONFIDENTIAL TREATMENT REQUESTED Collaboration and Option Agreement - Confidential - Page 42 SCHEDULE 1.24
Invoice Requirement. 38 12.20. Hardship............................................................................................38 Exhibit A Form of License, Development and Commercialization Agreement Exhibit B Form of Invoice Schedule 1.13 Excluded Compounds and Excluded Kinases Schedule 2.4.3 Development Candidate Criteria First Revised and Restated Research and Early Development Agreement -- Confidential -- Page ii FIRST REVISED AND RESTATED RESEARCH AND EARLY DEVELOPMENT AGREEMENT First Revised and Restated Agreement made this 3rd day of February, 2004, (as so revised and restated, the "Research Agreement"), revising and restating that certain Research And Early Development Agreement dated May 8, 2000 (the "Original Agreement"), between VERTEX PHARMACEUTICALS INCORPORATED ("VERTEX"), a Massachusetts corporation with principal offices at 000 Xxxxxxx Xxxxxx, Xxxxxxxxx, XX 00000-0000, and NOVARTIS PHARMA AG ("NOVARTIS"), a Swiss corporation with principal offices at Xxxxxxxxxxxx 00, XX-0000 Xxxxx, Xxxxxxxxxxx. This Research Agreement is intended by the parties to replace and supercede the rights and obligations of the parties under the Original Agreement with respect to the subject matter thereof, except that the terms of the Original Agreement shall be deemed to govern the rights and obligations of the parties with respect to the Compounds known as VX-680 and VX-528, subject to the provisions of Section 4.8(b) of this Research Agreement.
Invoice Requirement. Contractor will be paid on the basis of, and in response to, separate monthly invoices submitted by Contractor to each General Manager, subject to their individual review and approval. Each such invoice shall (i) be Facility-specific; (ii) include a prorated (i.e., 1/12th) portion of the Management Fee, (iii) detail all Preventative Services performed; (iv) detail any Remedial Services performed; (v) detail recommendations as to the present and anticipated need for any other Routine or Non-Routine Work or for other conditions known to the Contractor;
Invoice Requirement. The Agency shall pay the Provider on the basis of monthly invoices submitted to the Agency contract manager in a manner that is acceptable to the Agency (see Exhibit C).
Invoice Requirement. Any amounts payable to Vertex hereunder shall be made within thirty days after receipt by CFFT, or its nominee designated for that purpose in advance by CFFT in writing to Vertex, of an invoice covering such payment. VERTEX PHARMACEUTICALS INCORPORATED By: /s/ XXXXXXX X. XXXXX Xxxxxxx X. Xxxxx Title: Senior Vice President and General Counsel CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INCORORATED By: /s/ XXXXXX XXXXX Xxxxxx Xxxxx Title: President and CEO Research Plan for the CFFT—Vertex Pharmaceuticals Collaboration May 10, 2004 [***] [***] • [***] • [***] • [***] • [***] • [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] / / [***] [***] [***] [***] [***] [***] [***] EXHIBIT 4.2 INITIAL BUDGET FOR RESEARCH PROGRAM Vertex/CFFT—CFTR Drug Discovery Budget 2004-2005 [***] QuickLinks Exhibit 99.2 RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT TABLE OF CONTENTS RESEARCH, DEVELOPMENT AND COMMECIALIZATION AGREEMENT ARTICLE I—DEFINITIONS ARTICLE II—RESEARCH PROGRAM ARTICLE III—DEVELOPMENT ARTICLE IV—PAYMENTS ARTICLE V—COMMERCIALIZATION; ROYALTIES ARTICLE VI—CONFIDENTIALITY ARTICLE VII—PUBLICATION ARTICLE VIII—INDEMNIFICATION ARTICLE IX—PATENTABLE INVENTIONS ARTICLE X—TERM AND TERMINATION ARTICLE XI—REPRESENTATIONS AND WARRANTIES ARTICLE XII—DISPUTE RESOLUTION ARTICLE XIII—MISCELLANEOUS PROVISIONS EXHIBIT 2.4 RESEARCH PLAN EXHIBIT 4.2
